GLP-1 benefits: what these drugs actually do beyond weight loss

Weight loss (the headline)

The most visible benefit is substantial, sustained weight loss. In the pivotal trials, semaglutide (Wegovy) averaged around 15% body-weight loss over 68 weeks, and tirzepatide (Zepbound) around 20% over 72 weeks, figures well beyond what diet and exercise alone typically achieve. That weight loss is itself the engine for several of the other benefits, because excess weight drives so many conditions.

Blood-sugar control

These drugs began as diabetes medications, and that remains a core benefit: they lower blood sugar (A1C) meaningfully in type 2 diabetes, with a low risk of hypoglycemia on their own. For many people that means better glucose control on a once-weekly injection, which is why Ozempic, Mounjaro, and Trulicity are diabetes brands first.

Cardiovascular risk

This is one of the strongest and most important findings. In the SELECT trial of more than 17,000 people with cardiovascular disease and overweight or obesity but not diabetes, semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death). That is a hard outcome, not a surrogate marker, and it is why the cardiovascular benefit is now part of the label. Our heart-health guide covers it.

Obstructive sleep apnea

In 2024, Zepbound (tirzepatide) became the first medication approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial, which showed large reductions in breathing interruptions during sleep. For weight-linked sleep apnea, that is a genuine second benefit. Our sleep apnea guide covers it.

The mental benefit: food noise

Less measurable but widely reported: the quieting of "food noise," the constant background pull toward food. Many people describe this as the most life-changing part, because it makes eating a decision again rather than a compulsion. It is not a formal trial endpoint, but it is real and consistent enough across users to count. Our food noise guide explains it.

Emerging and researched benefits

Research is actively looking at effects on the liver (metabolic liver disease), kidney outcomes, and other areas, some of which are already producing new trials and approvals across the drug class. These are promising rather than settled, and worth watching rather than counting on today.

The honest balance

Benefits are one side of a two-sided ledger. They apply while you take the drug, they come with the gastrointestinal side effects and the class cautions (pancreatitis vigilance, gallbladder risk, the thyroid boxed warning), and stopping tends to reverse them. Weighing all of that with a prescriber is the point; our side-effect guide covers the other side of the balance so the decision is a real one.